<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999114</url>
  </required_header>
  <id_info>
    <org_study_id>BUP1025</org_study_id>
    <nct_id>NCT01999114</nct_id>
  </id_info>
  <brief_title>The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ECG effects of 10, 40, and 80 mcg/hr
      buprenorphine delivered by BTDS alone, or by BTDS dosed with naltrexone, relative to placebo
      in healthy male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)</measure>
    <time_frame>Baseline to Day 6</time_frame>
    <description>The effects of 10 mcg/hr buprenorphine (Day 6) delivered by BTDS alone, or by BTDS dosed with naltrexone, and naltrexone alone on cardiac repolarization, were assessed based on the corrected QT interval since HR inversely affects QT duration. The time-matched analysis was conducted as the primary endpoint as recommended by ICH E14, with the 2-sided 90% confidence interval for each treatment at each time point showing the placebo- and baseline-corrected (ΔΔ) analysis for QTcI. The effect of BTDS 10 on QT intervals was compared with the moxifloxacin-positive control after placebo and baseline correction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)</measure>
    <time_frame>Baseline to Day 13</time_frame>
    <description>The effects of 40 mcg/hr buprenorphine (Day 13) delivered by BTDS alone, or by BTDS dosed with naltrexone, and naltrexone alone on cardiac repolarization, were assessed based on the corrected QT interval since HR inversely affects QT duration. The time-matched analysis was conducted as the primary endpoint as recommended by ICH E14, with the 2-sided 90% confidence interval for each treatment at each time point showing the placebo- and baseline-corrected (ΔΔ) analysis for QTcI. The effect of BTDS 40 on QT intervals was compared with the moxifloxacin-positive control after placebo and baseline correction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)</measure>
    <time_frame>Baseline to Day 17</time_frame>
    <description>The effects of 80 mcg/hr buprenorphine (Day 17) delivered by BTDS alone, or by BTDS dosed with naltrexone, and naltrexone alone on cardiac repolarization, were assessed based on the corrected QT interval since HR inversely affects QT duration. The time-matched analysis was conducted as the primary endpoint as recommended by ICH E14, with the 2-sided 90% confidence interval for each treatment at each time point showing the placebo- and baseline-corrected (ΔΔ) analysis for QTcI. The effect of BTDS 80 on QT intervals was compared with the moxifloxacin-positive control after placebo and baseline correction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval</measure>
    <time_frame>Baseline to Day 6</time_frame>
    <description>Mean change from baseline for the BTDS 10 mcg/hr dose on Day 6, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR)</measure>
    <time_frame>Baseline to Day 6</time_frame>
    <description>Mean change from baseline for the BTDS 10 mcg/hr dose on Day 6, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval</measure>
    <time_frame>Baseline to Day 13</time_frame>
    <description>Mean change from baseline for the BTDS 40 mcg/hr dose on Day 13, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR)</measure>
    <time_frame>Baseline to Day 13</time_frame>
    <description>Mean change from baseline for the BTDS 40 mcg/hr dose on Day 13, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval</measure>
    <time_frame>Baseline to Day 17</time_frame>
    <description>Mean change from baseline for the BTDS 80 mcg/hr dose on Day 17, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR)</measure>
    <time_frame>Baseline to Day 17</time_frame>
    <description>Mean change from baseline for the BTDS 80 mcg/hr dose on Day 17, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG Morphology</measure>
    <time_frame>Baseline to Day 6</time_frame>
    <description>Morphological analyses were performed with regard to the digital ECG waveform interpretation as defined by a central ECG laboratory's cardiologist blinded to the study treatment. Changes from baseline to each day of treatment were evaluated separately. Any T-U wave complex that suggested an abnormal form compatible with an effect on cardiac repolarization was noted. New ECG morphological onset changes were presented as the percentage of subjects meeting the &quot;new&quot; criterion (&quot;new&quot; meant not present on any baseline ECG and became present on at least 1 on-treatment ECG) for the following variables:
Second degree heart block
Third degree heart block
Complete right bundle branch block (RBBB)
Complete left bundle branch block (LBBB)
ST segment changes (elevation and depression separately)
T-wave abnormalities (negative T waves only)
Myocardial infarction (MI) pattern
Any new abnormal U waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG Morphology</measure>
    <time_frame>Baseline to Day 13</time_frame>
    <description>Morphological analyses were performed with regard to the digital ECG waveform interpretation as defined by a central ECG laboratory's cardiologist blinded to the study treatment. Changes from baseline to each day of treatment were evaluated separately. Any T-U wave complex that suggested an abnormal form compatible with an effect on cardiac repolarization was noted. New ECG morphological onset changes were presented as the percentage of subjects meeting the &quot;new&quot; criterion (&quot;new&quot; meant not present on any baseline ECG and became present on at least 1 on-treatment ECG) for the following variables:
Second degree heart block
Third degree heart block
Complete right bundle branch block (RBBB)
Complete left bundle branch block (LBBB)
ST segment changes (elevation and depression separately)
T-wave abnormalities (negative T waves only)
Myocardial infarction (MI) pattern
Any new abnormal U waves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG Morphology</measure>
    <time_frame>Baseline to Day 17</time_frame>
    <description>Morphological analyses were performed with regard to the digital ECG waveform interpretation as defined by a central ECG laboratory's cardiologist blinded to the study treatment. Changes from baseline to each day of treatment were evaluated separately. Any T-U wave complex that suggested an abnormal form compatible with an effect on cardiac repolarization was noted. New ECG morphological onset changes were presented as the percentage of subjects meeting the &quot;new&quot; criterion (&quot;new&quot; meant not present on any baseline ECG and became present on at least 1 on-treatment ECG) for the following variables:
Second degree heart block
Third degree heart block
Complete right bundle branch block (RBBB)
Complete left bundle branch block (LBBB)
ST segment changes (elevation and depression separately)
T-wave abnormalities (negative T waves only)
Myocardial infarction (MI) pattern
Any new abnormal U waves</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">328</enrollment>
  <condition>ECG Effects</condition>
  <arm_group>
    <arm_group_label>BTDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTDS with naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone 50 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin 400-mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine transdermal patch</intervention_name>
    <description>Buprenorphine patch applied transdermally</description>
    <arm_group_label>BTDS</arm_group_label>
    <arm_group_label>BTDS with naltrexone</arm_group_label>
    <other_name>Butrans</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone tablet</intervention_name>
    <description>Naltrexone tablet; 1 tablet taken orally every 12 hours</description>
    <arm_group_label>BTDS with naltrexone</arm_group_label>
    <arm_group_label>Naltrexone</arm_group_label>
    <other_name>ReVia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos (for TDS and for naltrexone and for moxifloxacin)</intervention_name>
    <description>Matching placebos</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin tablet</intervention_name>
    <description>Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Avelox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent.

          -  Males and females aged 18 to 55, inclusive.

          -  Body weight ranging from 50 to 100 kilograms (kg) (110 to 220 lbs) and body mass index
             (BMI) ranging from 18 to 30 (kg/m2), inclusive.

          -  Healthy and free of significant abnormal findings as determined by medical history,
             physical examination, clinical laboratory values, vital signs, and resting 12-lead
             ECG.

          -  Females of child-bearing potential must be using an adequate and reliable method of
             contraception (ie, barrier with additional spermicidal foam or jelly, intra-uterine
             device, hormonal contraception). Females who are postmenopausal must have been
             postmenopausal ≥ 1 year and have elevated serum follicle stimulating hormone (FSH).

          -  Willing to eat the food supplied during the study.

          -  Willing to refrain from strenuous exercise during the entire study. Subjects will not
             begin a new exercise program nor participate in any unusually strenuous physical
             exertion.

          -  All 8 anatomical transdermal system (TDS) application sites (upper back, upper chest,
             upper outer arm, or lateral thorax) must be acceptable for study use.

        Exclusion Criteria:

          -  Females who are pregnant (positive beta human chorionic gonadotropin test) or
             lactating.

          -  Current or recent (within 5 years) history of drug or alcohol abuse.

          -  History or any current conditions that might interfere with drug absorption
             (transdermal or gastrointestinal), distribution, metabolism or excretion.

          -  Use of an opioid-containing medication in the past 30 days preceding the initial dose
             in this study.

          -  Known allergy to buprenorphine, any excipient of BTDS, opioids, psychotropic or
             hypnotic drugs, and/or moxifloxacin or any member of the quinolone class drugs.

          -  Any history of frequent nausea or emesis regardless of etiology.

          -  Any history of seizures or head trauma with sequelae.

          -  Participation in a clinical drug study during the 30 days preceding the initial dose
             in this study.

          -  Any significant illness during the 30 days preceding the initial dose in this study.

          -  Use of any medication including thyroid hormonal therapy (hormonal contraception and
             hormonal replacement therapy in the form of estrogen with or without progestin is
             allowed), vitamins, herbal and/or mineral supplements during the 7 days preceding the
             initial dose.

          -  Any personal or family history of prolonged QT interval or disorders of cardiac
             rhythm.

          -  Abnormal cardiac conditions including hypertension.

          -  Abnormal cardiac condition denoted by any of the following:

               -  QTcF interval &gt; 450 milliseconds (msec)

               -  PR interval &gt; 240 msec or QRS &gt; 110 msec

               -  Evidence of second- or third-degree atrioventricular (AV) block

               -  Pathological Q-waves (defined as Q-wave &gt;40 msec or depth &gt; 0.5 mV)

               -  Evidence of ventricular pre-excitation, complete left bundle branch block, right
                  bundle branch block (RBBB), or incomplete RBBB

               -  With a resting heart rate outside the range of 45 to 85 beats per minute (bpm)

          -  Abnormalities on physical examination, vital signs, ECG, or clinical laboratory
             values, unless those abnormalities were judged clinically insignificant by the
             investigator.

          -  Oxygen saturation (SpO2) ≤ 94% as measured by pulse oximetry.

          -  Refusal to abstain from caffeine or xanthine containing beverages entirely during
             confinement.

          -  Refusal to abstain from consumption of alcoholic beverages 48 hours prior to initial
             study drug administration and any time during study.

          -  History of smoking or use of nicotine products within 45 days of study drug
             administration or a positive urine cotinine test

          -  Blood or blood products donated within 30 days prior to study drug administration or
             anytime during the study.

          -  Positive results of urine drug screen or alcohol screen.

          -  Positive results of hepatitis B surface antigen (HBsAg), hepatitis C antibody
             (anti-HCV).

          -  Positive naloxone challenge test.

          -  Presence of Gilbert's Syndrome, or any known hepatobiliary abnormalities.

          -  The investigator believes the subject to be unsuitable for reason(s) not specifically
             stated in the exclusion criteria.

          -  Subjects who have allergies or other contraindications to transdermal systems or patch
             adhesives.

          -  Clinically significant history of allergic reaction to wound dressings or elastoplast.

          -  Subjects with a dermatological disorder at any relevant patch application site that
             precludes proper placement and/or rotation of patch.

          -  Taking antihistamines within 72 hours prior to dosing or systemic or topical
             corticosteroids within 3 weeks prior to dosing.

          -  Subjects will not allow hair to be removed at the proposed patch application site
             which may prevent proper placement of the patch.

          -  Subjects for whom a proper assessment of possible application site reactions would be
             confounded by local skin conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD Phase I Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b</url>
    <description>Product Information</description>
  </link>
  <results_reference>
    <citation>Harris SC, Morganroth J, Ripa SR, Thorn MD, Colucci S. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials. Postgrad Med. 2017 Jan;129(1):69-80. doi: 10.1080/00325481.2017.1270156.</citation>
    <PMID>27927048</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <results_first_submitted>April 20, 2017</results_first_submitted>
  <results_first_submitted_qc>February 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2018</results_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <keyword>Opioid</keyword>
  <keyword>Transdermal</keyword>
  <keyword>ECG</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject First Visit: 15-March-2012; Last Subject Last Visit: 10-October-2012. The study was conducted at 1 medical/research site in the United States.</recruitment_details>
      <pre_assignment_details>Healthy adult subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BTDS</title>
          <description>Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr
Buprenorphine transdermal patch: Buprenorphine patch applied transdermally</description>
        </group>
        <group group_id="P2">
          <title>BTDS With Naltrexone</title>
          <description>Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
Buprenorphine transdermal patch: Buprenorphine patch applied transdermally
Naltrexone tablet: Naltrexone tablet; 1 tablet taken orally every 12 hours</description>
        </group>
        <group group_id="P3">
          <title>Naltrexone</title>
          <description>Naltrexone 50 mg tablets
Naltrexone tablet: Naltrexone tablet; 1 tablet taken orally every 12 hours</description>
        </group>
        <group group_id="P4">
          <title>Moxifloxacin</title>
          <description>Moxifloxacin 400-mg tablets
Moxifloxacin tablet: Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
Placebos (for BTDS and for naltrexone and for moxifloxacin): Matching placebos</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="65"/>
                <participants group_id="P5" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="62"/>
                <participants group_id="P5" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BTDS</title>
          <description>Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr
Buprenorphine transdermal patch: Buprenorphine patch applied transdermally</description>
        </group>
        <group group_id="B2">
          <title>BTDS With Naltrexone</title>
          <description>Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
Buprenorphine transdermal patch: Buprenorphine patch applied transdermally
Naltrexone tablet: Naltrexone tablet; 1 tablet taken orally every 12 hours</description>
        </group>
        <group group_id="B3">
          <title>Naltrexone</title>
          <description>Naltrexone 50 mg tablets
Naltrexone tablet: Naltrexone tablet; 1 tablet taken orally every 12 hours</description>
        </group>
        <group group_id="B4">
          <title>Moxifloxacin</title>
          <description>Moxifloxacin 400-mg tablets
Moxifloxacin tablet: Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
Placebos (for TDS and for naltrexone and for moxifloxacin): Matching placebos</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="66"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="65"/>
            <count group_id="B6" value="328"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="9.27"/>
                    <measurement group_id="B2" value="31.6" spread="8.97"/>
                    <measurement group_id="B3" value="34.0" spread="10.14"/>
                    <measurement group_id="B4" value="35.0" spread="10.03"/>
                    <measurement group_id="B5" value="33.0" spread="10.48"/>
                    <measurement group_id="B6" value="33.4" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="127"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)</title>
        <description>The effects of 10 mcg/hr buprenorphine (Day 6) delivered by BTDS alone, or by BTDS dosed with naltrexone, and naltrexone alone on cardiac repolarization, were assessed based on the corrected QT interval since HR inversely affects QT duration. The time-matched analysis was conducted as the primary endpoint as recommended by ICH E14, with the 2-sided 90% confidence interval for each treatment at each time point showing the placebo- and baseline-corrected (ΔΔ) analysis for QTcI. The effect of BTDS 10 on QT intervals was compared with the moxifloxacin-positive control after placebo and baseline correction.</description>
        <time_frame>Baseline to Day 6</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.
The placebo treatment group is not presented; however, the placebo data were used as a correction factor for these time-matched analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only (Placebo-corrected ΔΔQTcI)</title>
            <description>BTDS 10 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone (Placebo-corrected ΔΔQTcI)</title>
            <description>BTDS 10 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone (Placebo-corrected ΔΔQTcI)</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin (Placebo-corrected ΔΔQTcI)</title>
            <description>Moxifloxacin 400 mg tablet (positive control)</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)</title>
          <description>The effects of 10 mcg/hr buprenorphine (Day 6) delivered by BTDS alone, or by BTDS dosed with naltrexone, and naltrexone alone on cardiac repolarization, were assessed based on the corrected QT interval since HR inversely affects QT duration. The time-matched analysis was conducted as the primary endpoint as recommended by ICH E14, with the 2-sided 90% confidence interval for each treatment at each time point showing the placebo- and baseline-corrected (ΔΔ) analysis for QTcI. The effect of BTDS 10 on QT intervals was compared with the moxifloxacin-positive control after placebo and baseline correction.</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.
The placebo treatment group is not presented; however, the placebo data were used as a correction factor for these time-matched analyses.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" lower_limit="1.09" upper_limit="5.63"/>
                    <measurement group_id="O2" value="5.37" lower_limit="2.70" upper_limit="8.03"/>
                    <measurement group_id="O3" value="4.34" lower_limit="2.21" upper_limit="6.48"/>
                    <measurement group_id="O4" value="11.90" lower_limit="8.82" upper_limit="14.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)</title>
        <description>The effects of 40 mcg/hr buprenorphine (Day 13) delivered by BTDS alone, or by BTDS dosed with naltrexone, and naltrexone alone on cardiac repolarization, were assessed based on the corrected QT interval since HR inversely affects QT duration. The time-matched analysis was conducted as the primary endpoint as recommended by ICH E14, with the 2-sided 90% confidence interval for each treatment at each time point showing the placebo- and baseline-corrected (ΔΔ) analysis for QTcI. The effect of BTDS 40 on QT intervals was compared with the moxifloxacin-positive control after placebo and baseline correction.</description>
        <time_frame>Baseline to Day 13</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.
The placebo treatment group is not presented; however, the placebo data were used as a correction factor for these time-matched analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only (Placebo-corrected ΔΔQTcI)</title>
            <description>BTDS 40 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone (Placebo-corrected ΔΔQTcI)</title>
            <description>BTDS 40 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone (Placebo-corrected ΔΔQTcI)</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin (Placebo-corrected ΔΔQTcI)</title>
            <description>Moxifoxacin 400 mg tablet (positive control)</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)</title>
          <description>The effects of 40 mcg/hr buprenorphine (Day 13) delivered by BTDS alone, or by BTDS dosed with naltrexone, and naltrexone alone on cardiac repolarization, were assessed based on the corrected QT interval since HR inversely affects QT duration. The time-matched analysis was conducted as the primary endpoint as recommended by ICH E14, with the 2-sided 90% confidence interval for each treatment at each time point showing the placebo- and baseline-corrected (ΔΔ) analysis for QTcI. The effect of BTDS 40 on QT intervals was compared with the moxifloxacin-positive control after placebo and baseline correction.</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.
The placebo treatment group is not presented; however, the placebo data were used as a correction factor for these time-matched analyses.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.16" lower_limit="6.52" upper_limit="11.81"/>
                    <measurement group_id="O2" value="5.12" lower_limit="2.26" upper_limit="7.97"/>
                    <measurement group_id="O3" value="1.81" lower_limit="-0.70" upper_limit="4.33"/>
                    <measurement group_id="O4" value="10.68" lower_limit="7.06" upper_limit="14.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)</title>
        <description>The effects of 80 mcg/hr buprenorphine (Day 17) delivered by BTDS alone, or by BTDS dosed with naltrexone, and naltrexone alone on cardiac repolarization, were assessed based on the corrected QT interval since HR inversely affects QT duration. The time-matched analysis was conducted as the primary endpoint as recommended by ICH E14, with the 2-sided 90% confidence interval for each treatment at each time point showing the placebo- and baseline-corrected (ΔΔ) analysis for QTcI. The effect of BTDS 80 on QT intervals was compared with the moxifloxacin-positive control after placebo and baseline correction.</description>
        <time_frame>Baseline to Day 17</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.
The placebo treatment group is not presented; however, the placebo data were used as a correction factor for these time-matched analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only (Placebo-corrected ΔΔQTcI)</title>
            <description>BTDS 80 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone (Placebo-corrected ΔΔQTcI)</title>
            <description>BTDS 80 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone (Placebo-corrected ΔΔQTcI)</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin (Placebo-corrected ΔΔQTcI)</title>
            <description>Moxifloxacin 400 mg tablet (positive control)</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)</title>
          <description>The effects of 80 mcg/hr buprenorphine (Day 17) delivered by BTDS alone, or by BTDS dosed with naltrexone, and naltrexone alone on cardiac repolarization, were assessed based on the corrected QT interval since HR inversely affects QT duration. The time-matched analysis was conducted as the primary endpoint as recommended by ICH E14, with the 2-sided 90% confidence interval for each treatment at each time point showing the placebo- and baseline-corrected (ΔΔ) analysis for QTcI. The effect of BTDS 80 on QT intervals was compared with the moxifloxacin-positive control after placebo and baseline correction.</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.
The placebo treatment group is not presented; however, the placebo data were used as a correction factor for these time-matched analyses.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.46" lower_limit="8.78" upper_limit="14.14"/>
                    <measurement group_id="O2" value="4.47" lower_limit="1.71" upper_limit="7.23"/>
                    <measurement group_id="O3" value="1.50" lower_limit="-1.15" upper_limit="4.15"/>
                    <measurement group_id="O4" value="10.78" lower_limit="7.20" upper_limit="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval</title>
        <description>Mean change from baseline for the BTDS 10 mcg/hr dose on Day 6, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
        <time_frame>Baseline to Day 6</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only</title>
            <description>BTDS 10 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone</title>
            <description>BTDS 10 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin 400 mg tablet (positive control)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval</title>
          <description>Mean change from baseline for the BTDS 10 mcg/hr dose on Day 6, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="5.9"/>
                    <measurement group_id="O2" value="2.9" spread="8.7"/>
                    <measurement group_id="O3" value="1.5" spread="4.6"/>
                    <measurement group_id="O4" value="6.9" spread="5.1"/>
                    <measurement group_id="O5" value="-0.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="6.1"/>
                    <measurement group_id="O2" value="1.5" spread="6.6"/>
                    <measurement group_id="O3" value="0.9" spread="5.4"/>
                    <measurement group_id="O4" value="9.1" spread="5.2"/>
                    <measurement group_id="O5" value="0.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="7.2"/>
                    <measurement group_id="O2" value="2.4" spread="5.0"/>
                    <measurement group_id="O3" value="2.1" spread="4.2"/>
                    <measurement group_id="O4" value="0.3" spread="6.1"/>
                    <measurement group_id="O5" value="0.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.1"/>
                    <measurement group_id="O2" value="0.7" spread="1.9"/>
                    <measurement group_id="O3" value="0.6" spread="1.4"/>
                    <measurement group_id="O4" value="-0.2" spread="1.9"/>
                    <measurement group_id="O5" value="0.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="11.2"/>
                    <measurement group_id="O2" value="5.6" spread="22.1"/>
                    <measurement group_id="O3" value="2.6" spread="8.8"/>
                    <measurement group_id="O4" value="2.6" spread="11.9"/>
                    <measurement group_id="O5" value="-3.4" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate (HR)</title>
        <description>Mean change from baseline for the BTDS 10 mcg/hr dose on Day 6, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
        <time_frame>Baseline to Day 6</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only</title>
            <description>BTDS 10 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone</title>
            <description>BTDS 10 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin 400 mg tablet (positive control)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate (HR)</title>
          <description>Mean change from baseline for the BTDS 10 mcg/hr dose on Day 6, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="3.8"/>
                    <measurement group_id="O2" value="-1.3" spread="6.8"/>
                    <measurement group_id="O3" value="-0.5" spread="2.9"/>
                    <measurement group_id="O4" value="2.0" spread="4.1"/>
                    <measurement group_id="O5" value="1.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval</title>
        <description>Mean change from baseline for the BTDS 40 mcg/hr dose on Day 13, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
        <time_frame>Baseline to Day 13</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only</title>
            <description>BTDS 40 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone</title>
            <description>BTDS 40 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin 400 mg tablets</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval</title>
          <description>Mean change from baseline for the BTDS 40 mcg/hr dose on Day 13, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="7.8"/>
                    <measurement group_id="O2" value="1.1" spread="9.6"/>
                    <measurement group_id="O3" value="-1.3" spread="6.2"/>
                    <measurement group_id="O4" value="5.6" spread="6.6"/>
                    <measurement group_id="O5" value="-1.6" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="8.8"/>
                    <measurement group_id="O2" value="-1.1" spread="8.0"/>
                    <measurement group_id="O3" value="-2.2" spread="6.8"/>
                    <measurement group_id="O4" value="8.0" spread="7.0"/>
                    <measurement group_id="O5" value="0.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="8.7"/>
                    <measurement group_id="O2" value="4.4" spread="5.9"/>
                    <measurement group_id="O3" value="3.2" spread="9.1"/>
                    <measurement group_id="O4" value="1.3" spread="6.6"/>
                    <measurement group_id="O5" value="2.0" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.8"/>
                    <measurement group_id="O2" value="0.9" spread="2.4"/>
                    <measurement group_id="O3" value="1.3" spread="2.0"/>
                    <measurement group_id="O4" value="-0.2" spread="2.6"/>
                    <measurement group_id="O5" value="0.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="16.0"/>
                    <measurement group_id="O2" value="5.5" spread="20.8"/>
                    <measurement group_id="O3" value="0.4" spread="11.3"/>
                    <measurement group_id="O4" value="0.9" spread="13.8"/>
                    <measurement group_id="O5" value="-5.1" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate (HR)</title>
        <description>Mean change from baseline for the BTDS 40 mcg/hr dose on Day 13, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
        <time_frame>Baseline to Day 13</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only</title>
            <description>BTDS 40 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone</title>
            <description>BTDS 40 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin 400 mg tablet (positive control)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate (HR)</title>
          <description>Mean change from baseline for the BTDS 40 mcg/hr dose on Day 13, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="5.9"/>
                    <measurement group_id="O2" value="-1.9" spread="6.3"/>
                    <measurement group_id="O3" value="-0.8" spread="3.7"/>
                    <measurement group_id="O4" value="2.3" spread="5.0"/>
                    <measurement group_id="O5" value="1.6" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval</title>
        <description>Mean change from baseline for the BTDS 80 mcg/hr dose on Day 17, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
        <time_frame>Baseline to Day 17</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only</title>
            <description>BTDS 80 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone</title>
            <description>BTDS 80 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin 400 mg tablets</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>QTcF and QTcB for Historical Purposes, PR Interval, QRS Interval, and Uncorrected QT Interval</title>
          <description>Mean change from baseline for the BTDS 80 mcg/hr dose on Day 17, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="7.6"/>
                    <measurement group_id="O2" value="1.8" spread="8.6"/>
                    <measurement group_id="O3" value="-0.8" spread="7.4"/>
                    <measurement group_id="O4" value="6.7" spread="6.4"/>
                    <measurement group_id="O5" value="-0.4" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="9.0"/>
                    <measurement group_id="O2" value="-0.8" spread="8.7"/>
                    <measurement group_id="O3" value="-1.7" spread="7.9"/>
                    <measurement group_id="O4" value="9.3" spread="7.7"/>
                    <measurement group_id="O5" value="1.2" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="8.9"/>
                    <measurement group_id="O2" value="5.8" spread="5.5"/>
                    <measurement group_id="O3" value="4.3" spread="5.7"/>
                    <measurement group_id="O4" value="3.8" spread="10.9"/>
                    <measurement group_id="O5" value="3.0" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="3.0"/>
                    <measurement group_id="O2" value="1.5" spread="2.3"/>
                    <measurement group_id="O3" value="1.3" spread="1.9"/>
                    <measurement group_id="O4" value="0.2" spread="2.8"/>
                    <measurement group_id="O5" value="0.6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="13.9"/>
                    <measurement group_id="O2" value="7.1" spread="17.1"/>
                    <measurement group_id="O3" value="0.8" spread="12.6"/>
                    <measurement group_id="O4" value="1.4" spread="11.9"/>
                    <measurement group_id="O5" value="-3.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate (HR)</title>
        <description>Mean change from baseline for the BTDS 80 mcg/hr dose on Day 17, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
        <time_frame>Baseline to Day 17</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only</title>
            <description>BTDS 80 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone</title>
            <description>BTDS 80 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin 400 mg tablet (positive control)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate (HR)</title>
          <description>Mean change from baseline for the BTDS 80 mcg/hr dose on Day 17, presented as time-averaged mean change from baseline for BTDS only, BTDS with naltrexone, naltrexone alone, moxifloxacin, and placebo.</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="4.9"/>
                    <measurement group_id="O2" value="-2.4" spread="5.6"/>
                    <measurement group_id="O3" value="-0.8" spread="3.9"/>
                    <measurement group_id="O4" value="2.5" spread="4.4"/>
                    <measurement group_id="O5" value="1.5" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECG Morphology</title>
        <description>Morphological analyses were performed with regard to the digital ECG waveform interpretation as defined by a central ECG laboratory's cardiologist blinded to the study treatment. Changes from baseline to each day of treatment were evaluated separately. Any T-U wave complex that suggested an abnormal form compatible with an effect on cardiac repolarization was noted. New ECG morphological onset changes were presented as the percentage of subjects meeting the &quot;new&quot; criterion (&quot;new&quot; meant not present on any baseline ECG and became present on at least 1 on-treatment ECG) for the following variables:
Second degree heart block
Third degree heart block
Complete right bundle branch block (RBBB)
Complete left bundle branch block (LBBB)
ST segment changes (elevation and depression separately)
T-wave abnormalities (negative T waves only)
Myocardial infarction (MI) pattern
Any new abnormal U waves</description>
        <time_frame>Baseline to Day 6</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only</title>
            <description>BTDS 10 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone</title>
            <description>BTDS 10 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin 400 mg tablet (positive control)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Morphology</title>
          <description>Morphological analyses were performed with regard to the digital ECG waveform interpretation as defined by a central ECG laboratory's cardiologist blinded to the study treatment. Changes from baseline to each day of treatment were evaluated separately. Any T-U wave complex that suggested an abnormal form compatible with an effect on cardiac repolarization was noted. New ECG morphological onset changes were presented as the percentage of subjects meeting the &quot;new&quot; criterion (&quot;new&quot; meant not present on any baseline ECG and became present on at least 1 on-treatment ECG) for the following variables:
Second degree heart block
Third degree heart block
Complete right bundle branch block (RBBB)
Complete left bundle branch block (LBBB)
ST segment changes (elevation and depression separately)
T-wave abnormalities (negative T waves only)
Myocardial infarction (MI) pattern
Any new abnormal U waves</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New abnormal U waves</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New T wave (negative) inverted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New ST segment depression changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New ST segment elevation changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New complete RBBB &amp; LBBB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New 2nd or 3rd degree heart block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECG Morphology</title>
        <description>Morphological analyses were performed with regard to the digital ECG waveform interpretation as defined by a central ECG laboratory's cardiologist blinded to the study treatment. Changes from baseline to each day of treatment were evaluated separately. Any T-U wave complex that suggested an abnormal form compatible with an effect on cardiac repolarization was noted. New ECG morphological onset changes were presented as the percentage of subjects meeting the &quot;new&quot; criterion (&quot;new&quot; meant not present on any baseline ECG and became present on at least 1 on-treatment ECG) for the following variables:
Second degree heart block
Third degree heart block
Complete right bundle branch block (RBBB)
Complete left bundle branch block (LBBB)
ST segment changes (elevation and depression separately)
T-wave abnormalities (negative T waves only)
Myocardial infarction (MI) pattern
Any new abnormal U waves</description>
        <time_frame>Baseline to Day 13</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only</title>
            <description>BTDS 40 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone</title>
            <description>BTDS 40 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin 400 mg tablet (positive control)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Morphology</title>
          <description>Morphological analyses were performed with regard to the digital ECG waveform interpretation as defined by a central ECG laboratory's cardiologist blinded to the study treatment. Changes from baseline to each day of treatment were evaluated separately. Any T-U wave complex that suggested an abnormal form compatible with an effect on cardiac repolarization was noted. New ECG morphological onset changes were presented as the percentage of subjects meeting the &quot;new&quot; criterion (&quot;new&quot; meant not present on any baseline ECG and became present on at least 1 on-treatment ECG) for the following variables:
Second degree heart block
Third degree heart block
Complete right bundle branch block (RBBB)
Complete left bundle branch block (LBBB)
ST segment changes (elevation and depression separately)
T-wave abnormalities (negative T waves only)
Myocardial infarction (MI) pattern
Any new abnormal U waves</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New abnormal U waves</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New T wave (negative) inverted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New ST segment depression changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New ST segment elevation changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New complete RBBB &amp; LBBB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New 2nd or 3rd degree heart block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECG Morphology</title>
        <description>Morphological analyses were performed with regard to the digital ECG waveform interpretation as defined by a central ECG laboratory's cardiologist blinded to the study treatment. Changes from baseline to each day of treatment were evaluated separately. Any T-U wave complex that suggested an abnormal form compatible with an effect on cardiac repolarization was noted. New ECG morphological onset changes were presented as the percentage of subjects meeting the &quot;new&quot; criterion (&quot;new&quot; meant not present on any baseline ECG and became present on at least 1 on-treatment ECG) for the following variables:
Second degree heart block
Third degree heart block
Complete right bundle branch block (RBBB)
Complete left bundle branch block (LBBB)
ST segment changes (elevation and depression separately)
T-wave abnormalities (negative T waves only)
Myocardial infarction (MI) pattern
Any new abnormal U waves</description>
        <time_frame>Baseline to Day 17</time_frame>
        <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
        <group_list>
          <group group_id="O1">
            <title>BTDS Only</title>
            <description>BTDS 80 mcg/hr</description>
          </group>
          <group group_id="O2">
            <title>BTDS With Naltrexone</title>
            <description>BTDS 80 mcg/hr and naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone Alone</title>
            <description>Naltrexone 50 mg tablets</description>
          </group>
          <group group_id="O4">
            <title>Moxifloxacin</title>
            <description>Moxifloxacin 400 mg tablet (positive control)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Morphology</title>
          <description>Morphological analyses were performed with regard to the digital ECG waveform interpretation as defined by a central ECG laboratory's cardiologist blinded to the study treatment. Changes from baseline to each day of treatment were evaluated separately. Any T-U wave complex that suggested an abnormal form compatible with an effect on cardiac repolarization was noted. New ECG morphological onset changes were presented as the percentage of subjects meeting the &quot;new&quot; criterion (&quot;new&quot; meant not present on any baseline ECG and became present on at least 1 on-treatment ECG) for the following variables:
Second degree heart block
Third degree heart block
Complete right bundle branch block (RBBB)
Complete left bundle branch block (LBBB)
ST segment changes (elevation and depression separately)
T-wave abnormalities (negative T waves only)
Myocardial infarction (MI) pattern
Any new abnormal U waves</description>
          <population>The full analysis for ECG population was the group of subjects who were randomized, received at least 1 dose of study drug, and had at least 1 time-matched baseline and 1 on-treatment ECG.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>New abnormal U waves</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New T wave (negative) inverted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New ST segment depression changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New ST segment elevation changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New complete RBBB &amp; LBBB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New 2nd or 3rd degree heart block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) and serious adverse events (SAEs) were reported from start of study participation through the period beyond study completion; AEs were reported through 7 days and SAEs through 30 days after last study drug dose, or until last study visit, whichever was later.</time_frame>
      <desc>AEs were learned of through spontaneous reports or subject interview.</desc>
      <group_list>
        <group group_id="E1">
          <title>BTDS</title>
          <description>Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr
Buprenorphine transdermal patch: Buprenorphine patch applied transdermally</description>
        </group>
        <group group_id="E2">
          <title>BTDS With Naltrexone</title>
          <description>Buprenorphine transdermal patches 10, 40 (2 x 20) and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
Buprenorphine transdermal patch: Buprenorphine patch applied transdermally
Naltrexone tablet: Naltrexone tablet; 1 tablet taken orally every 12 hours</description>
        </group>
        <group group_id="E3">
          <title>Naltrexone</title>
          <description>Naltrexone 50 mg tablets
Naltrexone tablet: Naltrexone tablet; 1 tablet taken orally every 12 hours</description>
        </group>
        <group group_id="E4">
          <title>Moxifloxacin</title>
          <description>Moxifloxacin 400-mg tablets
Moxifloxacin tablet: Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
Placebos (for TDS and for naltrexone and for moxifloxacin): Matching placebos</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <description>Onset of event occurred before study drug administration.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Infrequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Application site papules</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Feeling drunk</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Application site pustules</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Leader</name_or_title>
      <organization>Purdue Pharma L.P.</organization>
      <phone>800-733-1333</phone>
      <email>stephen.harris@pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

